

University of Groningen

Sigma-1 Receptor Imaging in the Brain

Kuzhuppilly Ramakrishnan, Nisha

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date:
2014

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Kuzhuppilly Ramakrishnan, N. (2014). *Sigma-1 Receptor Imaging in the Brain: Cerebral sigma-1 receptors and cognition: Small-animal PET studies using 11C-SA4503*. [Thesis fully internal (DIV), University of Groningen]. s.n.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.



The cholinergic system, sigma-1 receptors and cognition

**Aren van Waarde¹, Nisha K. Ramakrishnan¹,
Anna A. Rybczynska¹, Philip H. Elsinga¹,
Kiichi Ishiwata², Ingrid M. Nijholt³, Paul G.M. Luiten⁴
and Rudi A. Dierckx^{1,5}**

¹ Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands

² Positron Medical Center, Tokyo Metropolitan Institute of Gerontology, 1-1 Naka-cho, Itabashi-ku, Tokyo, 173-0022, Japan

³ Neurosciences, Section Functional Anatomy, University Medical Center Groningen, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands

⁴ Molecular Neurobiology, University of Groningen, Kercklaan 30, 9751 NN Haren, The Netherlands

⁵ Department of Nuclear Medicine, University Hospital Gent, De Pintelaan 185, 9000 Gent Belgium

Behav Brain Res. 2011 Aug 10;221(2):543-54

2

ABSTRACT

This article provides an overview of present knowledge regarding the relationship between the cholinergic system and sigma-1 receptors, and discusses potential applications of sigma-1 receptor agonists in the treatment of memory deficits and cognitive disorders. Sigma-1 receptors, initially considered as a subtype of the opioid family, are unique ligand-regulated molecular chaperones in the endoplasmic reticulum playing a modulatory role in intracellular calcium signaling and in the activity of several neurotransmitter systems, particularly the cholinergic and glutamatergic pathways. Several central nervous system (CNS) drugs show high to moderate affinities for sigma-1 receptors, including acetylcholinesterase inhibitors (donepezil), antipsychotics (haloperidol, rimcazole), selective serotonin reuptake inhibitors (fluvoxamine, sertraline) and monoamine oxidase inhibitors (clorgyline). These compounds can influence cognitive functions both via their primary targets and by activating sigma-1 receptors in the CNS. Sigma-1 agonists show powerful anti-amnesic and neuroprotective effects in a large variety of animal models of cognitive dysfunction involving, among others (i) pharmacologic target blockade (with muscarinic or NMDA receptor antagonists or p-chloroamphetamine); (ii) selective lesioning of cholinergic neurons; (iii) CNS administration of β -amyloid peptides; (iv) aging-induced memory loss, both in normal and senescent-accelerated rodents; (v) neurodegeneration induced by toxic compounds (CO, trimethyltin, cocaine), and (vi) prenatal restraint stress.

Keywords: Acetylcholine, cholinergic system, cognition, sigma-1 receptors, memory, anti-amnesic effects, sigma-1 agonists, neurodegenerative disease

INTRODUCTION

Cholinergic neurotransmission is a crucial process underlying memory and cognitive function. Cholinergic basal forebrain neurons in the nucleus basalis magnocellularis innervate the cerebral cortex, amygdaloid complex, or hippocampus and are essential for learning and memory formation (1) (2). Some cortical cholinergic activity is lost in normal aging. Patients suffering from AD or related dementias display a severe degeneration of cholinergic neurons and a corresponding loss of cortical cholinergic neurotransmission, which is one of the factors underlying their memory deficits (3) (4) (5). Administration of an anticholinergic drug, such as the muscarinic antagonist scopolamine, to experimental animals or healthy volunteers results in striking impairments of memory function which resemble Alzheimer dementia (6). On the other hand, acetylcholinesterase (AChE) inhibitors such as tacrine, physostigmine, rivastigmine and galantamine which suppress breakdown of the neurotransmitter acetylcholine, can temporarily improve memory function in some demented patients and in animal models of amnesia (7).

The sigma-1 receptor, a unique orphan receptor, is strongly expressed in neurons and in glia (8) (9). Neurosteroids, i.e. steroid hormones which are synthesized within the brain itself (10) (11) (12) (13), and sphingolipids (14) interact with sigma-1 sites which are now considered as ligand-regulated molecular chaperones modulating the activity of voltage-regulated and ligand-gated ion channels (15), intracellular calcium signaling (16), and the release of various neurotransmitters including acetylcholine (17) (18) (19) and glutamate (20). Occupancy of sigma-1 receptors by agonists causes translocation of the receptor protein from the endoplasmic reticulum to the cell membrane where the receptor can regulate ion channels and neurotransmitter release (21) (22) (Figure 1). The sigma-1 receptor is implicated in cellular differentiation (23) (24), neuroplasticity (25) (26), neuroprotection (27) (28), and cognitive functioning of the brain (29).

As both the cholinergic system and sigma-1 receptors are implied in cognition, we will in this article present an overview of current knowledge regarding the relationship between these neuronal pathways, and discuss potential applications of sigma-1 receptor agonists in the treatment of memory deficits and cognitive disorders.

ACETYLCHOLINE AND SIGMA-1 RECEPTOR FUNCTION

Sigma-1 receptor agonists are potent modulators of acetylcholine release, both *in vitro* and *in vivo*. Igmesine and (+)SKF 10,047 potentiate the KCl-evoked release of ³H-acetylcholine from rat hippocampal slices, and this effect can be blocked by the sigma antagonist haloperidol (18). The sigma-1 receptor agonist SA4503 dose-dependently increases the electrically evoked release of ³H-acetylcholine from hippocampal but not striatal slices isolated from rat brain (17).




Figure 1. Two schemes illustrating the hypothetical function of sigma-1 receptors. **Left:** Under baseline (resting) conditions, sigma-1 receptors (black oval) largely reside at the endoplasmic reticulum (ER), in association with ankyrin (green oval) and IP₃ receptors (red square). After agonist stimulation, sigma-1 receptors translocate to the plasmalemma where they can regulate ion channels (K⁺ or NMDA-receptor associated Ca²⁺), probably by direct protein-protein interactions. **Right:** Sigma-1 receptor agonists induce dissociation and translocation of sigma-1 receptors plus ankyrin from the sigma-1 receptor-IP₃ receptor complex. As a result, both the binding of IP₃ to its receptor and Ca²⁺ efflux from the ER are increased. Sigma-1 antagonists induce dissociation of only sigma-1 receptors from the complex, ankyrin remaining in place. Antagonists do not affect Ca²⁺ release when given alone, but they impede the potentiation of Ca²⁺ efflux by sigma-1 receptor agonists. After (193) (194).

Using *in vivo* microdialysis in freely moving rats, extracellular acetylcholine levels in the frontal cortex were found to be acutely and dose-dependently increased upon administration of the sigma-1 receptor agonists (+)-SKF 10,047, (+)-3-PPP, (\pm)-pentazocine and DTG. The effect of SKF 10,047 was stereoselective and it could be reversed by the sigma antagonist haloperidol (30) (31). In later experiments, (+)-SKF 10,047 was shown to also increase extracellular acetylcholine in the hippocampus in a stereoselective fashion and this effect could also be blocked by haloperidol (32). Regional differences in the stimulation of acetylcholine release by sigma-1 receptor agonists were subsequently observed. (+)-SKF 10,047 and DTG increased the release of acetylcholine in hippocampus and frontal cortex, but in the rat striatum, DTG had no and (+)-SKF 10,047 had only a marginal effect (33). Acetylcholine release in the hippocampus and frontal cortex was also strongly increased by the sigma-1 agonist SA4503, whereas acetylcholine release in the striatum was not affected (19) (34) (see Figure 2). The absence of an increase of striatal acetylcholine levels after administration of sigma-1 receptor agonists may





Figure 2. Upper panel: The sigma-1 receptor agonist SA4503 (10 mg/kg, per os, administered at time zero) increases extracellular acetylcholine levels in the frontal cortex but not in the striatum of freely moving rats. Lower panel: The effect of SA4503 on acetylcholine release is counteracted by the sigma-1 receptor antagonist NE-100 (0.5 mg/kg, co-administered with SA4503). After (19) (34).

be the reason why such drugs do not display some undesired side effects which are frequently seen after administration of acetylcholinesterase (AChE) inhibitors (19).

Since selective sigma-1 receptor agonists can facilitate the activity of cholinergic systems by stimulating acetylcholine release, particularly in the cortex and hippocampus, such drugs have the potential to ameliorate the memory impairments resulting from cholinergic dysfunction.

However, the capability of sigma-1 receptor agonists to ameliorate such impairments appears to be not solely due to modulation of residual acetylcholine release. In a recent study involving the potent and selective sigma-1 agonist (\pm)-PPCC (K_i at muscarinic receptors > 10,000 nM) and cholinergic lesions of varying severity, it was noted that the anti-amnesic effects of the sigma receptor agonist occur even in animals with *complete* cholinergic depletion, i.e. a total absence of cholinergic neurons in the basal forebrain nuclei (35). Pretreatment of animals with the sigma-1 receptor antagonist BD1047 blocked the anti-amnesic effects of (\pm)-PPCC (36). Thus, PPCC appears to improve cognition through sigma-1 receptors via additional, other mechanisms than stimulation of acetylcholine release. Some possible mechanisms are discussed in subsequent sections of this paper.

CHANGES OF SIGMA RECEPTOR DENSITY IN AGING AND NEURODEGENERATIVE DISEASE

When sigma-1 receptor density in the brain of aged (20-28 years old) and young adult (4-8 years old) monkeys was compared using the radioligand ^{11}C -SA4503 and PET, a highly significant increase (160-210%) of the binding potential (BP) was observed in aged animals (37). In a similar PET study in humans, ^{11}C -SA4503 binding was found to be unchanged in the human brain during healthy aging (38). This contrasts strikingly with the age-dependent loss of cholinergic, glutamatergic and dopaminergic receptors which occurs in primates (Figure 3).

Using autoradiography and the non-subtype-selective sigma ligand ^3H -DTG, a significant, 26% loss of binding sites was noted in the CA1 stratum pyramidale region of the hippocampus of Alzheimer's disease (AD) patients as compared to healthy controls. This loss of sigma receptors correlated with a 29% loss of pyramidal cells (39). These preliminary results suggested that sigma receptors are preferentially located on pyramidal cells in the CA1 region of the hippocampus.

In later PET studies, a loss of sigma-1 receptors from the brain of patients with AD was indeed observed (40). The BP of the sigma-1 ligand ^{11}C -SA4503 was significantly reduced (by 44 to 60%) in the frontal, temporal, and occipital lobe, cerebellum and thalamus of early AD patients as compared to healthy controls, but not in the hippocampus (41).

Two genetic variants of the sigma-1 receptor gene could affect the susceptibility of humans to AD, i.e. G-241T/C-240T (rs. 1799729) in the proximal promoter region and A61C (resulting in an amino acid substitution Q2P) in the first exon




Figure 3. Age-related increases of sigma-1 receptor density in rhesus monkey brain (upper left) compared to the decreases of muscarinic M₁/M₄, serotonin-2A (5-HT_{2A}), and dopamine D₂/D₃ receptor numbers with aging in human brain. Data from (195), (196), (197), and (198), respectively.

(42). The haplotype TT-C has been suggested to provide protection against AD. However, in a later study in a group of Polish patients (219 subjects with late-onset AD, 97 subjects with mild cognitive impairment and 308 nondemented subjects), no significant differences for the sigma-1 receptor allele, genotype, haplotype, and diplotype distributions were observed between the studied groups (43).

In a small group of patients with early Parkinson's disease ($n = 6$), the BP of ¹¹C-SA4503 was found to be significantly lower on the more affected than the less affected side of the anterior putamen, although there was no significant difference in BP between patients and controls (44). These data suggest that Parkinson's disease may be associated with a loss of sigma-1 receptors from the putamen, although the decrease is less striking than that observed in the cerebral cortex in AD.

In the rodent brain, sigma-1 receptor density was generally found to be preserved during aging. In a recent study involving healthy controls and senescent-accelerated mice (SAM), no differences between 6-, 9- and 12-month old rodents regarding the sigma-1 receptor density of various brain regions were observed, neither at the level of mRNA nor at the protein level (histochemistry, binding of ³H-(+)-SKF

10,047). However, in aged (12-mo) SAM, the antidepressant efficacy of the sigma-1 agonist igmesine was increased. This augmented response may be due to decreased levels of neurosteroids in these animals, particularly progesterone, a steroid with sigma-1 receptor antagonist action (45). The efficacy of sigma-1 receptor agonists is known to be inversely correlated to brain progesterone levels. In rats treated with chronic intracerebroventricular infusion of beta-amyloid(1-40) protein, or in beta-amyloid(25-35) peptide-treated mice, a significant decrease of cerebral progesterone levels is accompanied by a corresponding increase of the antidepressant activity of sigma-1 receptor agonists (46)(47). In another study on murine ageing, no differences in cerebral sigma-1 receptor density were observed between 2-mo and 24-mo old C57/BL6 mice, neither at the mRNA nor at the protein level (48).

Changes of sigma-1 and sigma-2 receptors in aging rat brain have been examined as well, by applying the radioligands ³H-SA4503, ³H-(+)pentazocine and ³H-DTG for binding studies in brain homogenates of 1.5 mo, 6-, 12- and 24-mo old Fisher-344 rats. The number of binding sites increased with aging, but the binding affinity of all ligands was decreased. Apparently, increases of receptor density (over)compensate for a reduced affinity of the receptor proteins to agonists in this rodent strain, and as a consequence, ligand binding is increased at old age (49), particularly at ages greater than 12 months. In an older study which used ³H-haloperidol (in combination with 50 nM unlabeled spiperone) to quantify sigma-1 plus sigma-2 receptors, receptor density in the brain of Fisher-344 rats was found to be unaltered between postnatal day 1 and age 12 months (50).

These findings of a preserved receptor density may perhaps not be generalized to all rat strains, since middle-aged Sprague-Dawley rats (5-6 mo old) were reported to have fewer sigma binding sites and sites with lower affinity for ³H-DTG than young adult animals (2-3 mo old). The older animals also exhibited a decreased behavioral response to sigma ligands injected into the substantia nigra (51). Another research group which used ³H-(+)-PPP confirmed that the binding sites for this ligand in the brain of Sprague-Dawley rats are present at high density during the perinatal period, and decline thereafter (52).

SIGMA LIGANDS IMPROVE COGNITION IN ANIMAL MODELS OF COGNITIVE IMPAIRMENT

Sigma-1 agonists (applied systemically) have shown anti-amnesic efficacy in several animal models of cognitive impairment. Both pharmacological and pathological models of amnesia have been examined (see Table 1 for an overview). These include: (i) cholinergic deficits (either induced by muscarinic antagonists or by lesions of the forebrain or the nucleus basalis resulting in a selective loss of cholinergic neurons); (ii) pathology induced by direct administration of β -amyloid(25-35) peptide to the rodent CNS, an animal model of Alzheimer's

disease; (iii) aging-induced losses of memory function, both in normal mice and SAM; (iv) neurodegeneration caused by exposure of animals to CO gas, or to trimethyltin; (v) prenatal stress (restraint, or exposure to cocaine), and (vi) glutamatergic, serotonergic, or calcium channel deficits induced by various drugs. The beneficial effects of sigma-1 receptor agonists on cognitive performance were detected in many different cognitive tests assessing short-term (working memory), long-term (reference memory), contextual or spatial memory processes.

For example, the sigma-1 receptor agonists (+)-SKF 10,047, pentazocine, DTG, (+)-3-PPP, igmesine and SA4503 prevented the scopolamine-induced amnesia of mice and rats in passive avoidance tasks, and the beneficial action of these compounds was blocked by sigma-1 receptor antagonists like NE-100. The anti-amnesic effects of SA4503 were blocked after sigma-1 receptor antisense administration, but not after administration of a mismatch oligodeoxynucleotide (34) (53) (54) (55) (56). Thus, activation of the sigma-1 receptor is involved in the improvement of cognition, and sigma-1 agonists have potential for the treatment of amnesia resulting from cholinergic dysfunction.

Sigma-1 receptor agonists such as (+)-SKF 10,047, (+)-pentazocine, DTG, PRE-084 and SA4503 also showed a potent anti-amnesic action against the cognitive deficits induced by NMDA-receptor blockade in mice and rats, e.g. treatment of animals with the non-competitive NMDA receptor antagonist dizocilpine before the learning test. These beneficial effects were stereoselective and were blocked by pretreatment of animals with sigma-1 antagonists such as BMY 14802, haloperidol or NE-100 (see Table 1 for references).

Neurotoxicity models of cognitive impairment which have been employed for testing cognitive enhancement by sigma-1 receptor agonists include repeated exposure of mice to CO gas and trimethyltin administration to rats. The former model results after 5 to 7 days in neuronal death that remains restricted to the CA1 area of the hippocampus (57). Trimethyltin administration results in damage of selective neural populations from limbic structures of the brain (58) (59). In such neurotoxicity models, similar findings were obtained as in the pharmacological models of amnesia, i.e. sigma-1 receptor agonists improved cognitive performance and this improvement could be blocked by sigma-1 receptor antagonists. However, in contrast to the scopolamine or dizocilpine-induced amnesia, cognitive impairments after exposure of animals to CO or trimethyltin were alleviated not only by sigma-1 agonists but also by sigma-2 receptor agonists.

In most behavioral tests, sigma-1 receptor agonists do not facilitate and sigma-1 receptor antagonists do not impede the learning of healthy control animals. Downregulation of sigma-1 receptor expression using an *in vivo* antisense approach also does not affect the learning ability of healthy mice submitted to a passive avoidance test (60) (61). However, sigma-1 receptor agonists improve the performance of pharmacologically or pathologically lesioned animals in standard learning tests, and this improvement in lesioned rodents can be blocked by sigma-1 receptor antagonists.

Table 1. Animal models in which sigma-1 agonists have shown anti-amnesic properties

Amnesia model	Species	σ_1 agonists
<i>Cholinergic deficit</i>		
Scopolamine	Rat	Igmesine, (+)-3-PPP, DTG
Scopolamine	Mouse	(+)-SKF 10,047, (\pm)-pentazocine
Scopolamine, Ibotenic acid forebrain lesion	Rat	SA4503
Scopolamine	Mouse	(+)-SKF 10,047
Ibotenic acid forebrain lesion	Rat	SA4503
Scopolamine	Mouse	DHEA-S, PREG-S
Scopolamine	Mouse	PRE084, SA4503
Scopolamine	Rat	OPC-14523
Nucleus basalis lesion	Rat	Fluoxetine
Scopolamine	Mouse	(+)-pentazocine, (+)-SKF 10,047
Scopolamine	Mouse	ANAVEX1-41
Scopolamine	Mouse	Dimemorfan
192IgG-saporin induced lesions, Atropine sulfate	Rat	(\pm)-PPCC
L-NAME 7-nitroindazole	Mouse	(+)-SKF 10,047(+)-pentazocine
<i>Amyloid-induced neurodegeneration</i>		
β -amyloid(25-35) peptide	Mouse	(+)-pentazocine, PRE084, SA4503, PREG-S, DHEA-S
β -amyloid(25-35) peptide	Mouse	Donepezil, PRE084
β -amyloid(25-35) peptide	Mouse	ANAVEX1-41
β -amyloid(25-35) peptide	Mouse	Dimemorfan
<i>Aging-related memory loss</i>		
Senescence-accelerated mouse	Mouse	Igmesine, PRE084
Normal aging	Rat	PRE084
Normal aging	Rat	OPC-14523
Normal aging	Mouse	PRE084
<i>Hypoxia-induced neurodegeneration</i>		
Repeated CO exposure	Mouse	(+)-SKF 10,047, DTG
Repeated CO exposure	Mouse	PRE084, DTG, BD1008
Repeated CO exposure	Mouse	DHEA
Repeated CO exposure	Mouse	Donepezil, igmesine

σ_1 antagonists	Other drugs used	Behavioral tests	Reference
None	Piracetam	Passive avoidance	(151)
None	Ritanserlin, mian-serin, tacrine, physostigmine	Passive avoidance	(54)
Haloperidol, NE-100	None	Passive avoidance	(152)
Haloperidol, NE-100	(-)-SKF 10,047, physostigmine	Passive avoidance	(56)
none	None	Morris water maze	(153)
Progesterone NE-100	None	Y-maze, water maze	(154)
Antisense NE-100	mismatch antisense	Y-maze, passive avoidance	(155)
NE-100	None	Morris water maze	(156)
None	None	Active avoidance	(157)
antisense, NE-100	(-)-pentazocine, U-50,488H	Y-maze	(158) (159) (160)
antisense, BD1047	None	Y-maze, passive avoidance, water maze, forced swimming test	(161)
Haloperidol	None	Passive avoidance Water maze	(162)
BD1047	None	Morris water maze	(163)
NE-100	None	Y-maze	(164)
Haloperidol, BMY14802, progesterone	None	Y-maze, passive avoidance	(165)
BD1047	Tacrine, rivastigmine, galantamine	Y-maze, passive avoidance	(166)
BD1047	Scopolamine	Y-maze, passive avoidance, radial arm maze	(75)
Haloperidol	None	Passive avoidance Water maze	(167)
BMY14802	J01783	Y-maze, water maze, passive avoidance, open field	(168)
none	None	Water maze	(169)
NE-100	None	Morris water maze	(170)
none	None	Morris water maze	(171)
BMY14802	None	Y-maze, passive avoidance	(172)
NE-100, haloperidol	None	Passive avoidance	(173)
Pregnelone, NE-100	None	Y-maze, passive avoidance	(174)
BD1047	Tacrine, rivastigmine, galantamine	Y-maze, passive avoidance	(175)

Table 1. Continued

Amnesia model	Species	σ_1 agonists
Toxin-induced neurodegeneration (aspecific)		
Trimethyltin	Rat	Igmesine
Trimethyltin	Mouse	PRE084, DTG, BD1008
Prenatal stress		
Prenatal restraint	Rat	Igmesine
Prenatal cocaine exposure	Rat	Igmesine, DHEA
NMDA-receptor deficit		
Dizocilpine	Mouse	(+)-SKF 10,047, (+)-pentazocine, DTG
Dizocilpine	Rat	(+)-SKF 10,047
Dizocilpine	Mouse	DHEA-S
Dizocilpine	Mouse	SA4503
Dizocilpine	Rat	(+)-SKF 10,047, SA4503
Dizocilpine	Rat	SA4503, DHEA-S, PREG-S
Dizocilpine	Mouse	PRE084, SA4503
Dizocilpine	Mouse	PRE084, DHEA-S, PREG-S
Phencyclidine, dizocilpine	Mouse	SA4503, (+)-pentazocine, (+)-SKF 10,047
Dizocilpine	Mouse	Donepezil, igmesine
Phencyclidine	Mouse	Fluvoxamine, SA4503, DHEA-S
Phencyclidine	Mouse	Donepezil
Serotonergic deficit		
<i>p</i> -chloroamph-amine	Mouse	(+)-SKF 10,047, (\pm)-pentazocine
<i>p</i> -chloroamph-amine	Mouse	(+)-SKF 10,047, DTG, (+)-3-PPP
Ca²⁺ channel deficit		
nimodipine	Mouse	PRE084
Sigma receptor deficit		
CDEP	Mouse	(+)-SKF 10,047, DTG, (+)-3-PPP


σ_1 antagonists	Other drugs used	Behavioral tests	Reference
none	None	passive avoidance, radial arm maze	(176)
NE-100, haloperidol	None	Passive avoidance	(177)
BD1063	None	Y-maze, T-maze, water maze, passive avoidance	(178)
BD1063	None	T-maze, water maze, passive avoidance	(179)
BMY14802, NE-100	(-)SKF 10,047, (-)pentazocine	Y-maze, passive avoidance, elevated plus maze	(180)
	(-)SKF 10,047	Three-panel runway task	(181)
BMY14802, haloperidol		Y-maze, passive avoidance	(182)
Haloperidol, progesterone	L-NAME	Y-maze, passive avoidance	(183)
NE-100	None	Radial arm maze	(184)
Progesterone, NE-100	None	Radial arm maze	(185)
Antisense	Mismatch antisense	Y-maze, passive avoidance	(186)
Antisense	Mismatch antisense	Y-maze, passive avoidance	(187)
NE-100	D-cycloserine, L-NAME	One-trial water-finding task	(188)
Antisense, BD1047	Rivastigmine, tacrine	Y-maze, passive avoidance	(189)
NE-100	Paroxetine	Novel object recognition task	(190)
NE-100	Physostigmine	Novel object recognition task	(191)
none	Ritanserlin, mianserin, tacrine, physostigmine	Passive avoidance	(54)
none	(-)SKF 10,047, hemicholinium-3	Passive avoidance	(53)
BMY14802	None	Y-maze, passive avoidance, water maze	(129)
none	None	Passive avoidance	(192)

Neuroactive steroids (such as DHEA-S or pregnenolone sulfate) have similar effects as non-steroid sigma-1 receptor agonists, whereas progesterone behaves as a sigma-1 receptor antagonist. These observations suggest that sigma-1 receptors are not directly involved in learning or memory, but sigma-1 receptor agonists can modulate neural processes underlying cognition, particularly under pathological conditions.

However, in some publications pro-mnesic effects of sigma-1 receptor agonists have been reported. For example, the neurosteroids DHEA-S and PREG-S, when given either pre- or post-training, were found to facilitate retention of a modified learning task in mice in a dose-dependent manner with a bell-shaped dose-response curve. This action of the neurosteroids appears to be dependent on their interaction with sigma-1 receptors, since it can be blocked by concurrent administration of the sigma antagonist haloperidol (62). Long-term potentiation (LTP) in rat hippocampus, a process thought to be crucial for learning and memory, is facilitated after chronic (7 d) administration of the neurosteroid DHEA-S. This potentiation appears to be based on alterations in postsynaptic neurons since no changes were observed in presynaptic glutamate release. DHEA-S appears to act through sigma-1 receptors, since the potentiating effect is absent when sigma-1 receptor antagonists (NE-100, haloperidol) are co-administered with the neurosteroid (63). Another neurosteroid with sigma-1 receptor agonist action, PREG-S, has also been reported to facilitate LTP in the rodent hippocampus by a mechanism involving sigma-1 receptors and L-type calcium channels (64). The non-sulfated forms of the neurosteroids which lack the sigma-1 receptor agonist action (DHEA and PREG) do not potentiate LTP (65) (64). Paired-pulse facilitation in hippocampal neurons from adult rats, a short-term increase of the postsynaptic potential, is also potentiated by PREG-S and this potentiation is abolished after co-administration of sigma-1 receptor antagonists (66).

IMPROVEMENT OF COGNITIVE FUNCTION IN HUMANS

Fluvoxamine has been reported to be effective in improving cognitive impairments in an animal model of schizophrenia, in contrast to paroxetine (67). Interestingly, fluvoxamine but not paroxetine was also found to improve the lack of concentration, poor memory, slowness of mind, and poor executive function in a patient with schizophrenia (68). The affinity of fluvoxamine for sigma-1 receptors is more than 50 times higher than that of paroxetine, although both compounds are potent selective serotonin reuptake inhibitors (SSRIs) (69). High occupancy (up to 60%) of sigma-1 receptors in the human brain was observed with ¹¹C-SA4503 PET after a single oral dose of 200 mg fluvoxamine (70) (see Figure 4 for a similar occupancy study). These data suggest that sigma-1 receptor agonists including SSRIs with sigma-1 receptor agonist action, such as fluvoxamine, may be candidates for treating cognitive impairments in schizophrenia.



2

Figure 4. PET scans of the brain of a human volunteer, made with the sigma-1 receptor ligand ^{11}C -SA4503, at baseline (left) and after oral administration of an antipsychotic drug, interval 3 h (middle) and 10 h (right), respectively. The binding of ^{11}C -SA4503 was considerably reduced after occupancy of sigma-1 receptors by the antipsychotic drug. Data from our own group, not previously published.

Compounds which combine acetylcholinesterase (AChE) inhibition with sigma-1 receptor agonism exist as well, e.g. donepezil. A recent paper reported that therapeutic doses of donepezil result in considerable sigma-1 receptor occupancy in human brain (71). Sigma-1 receptor agonists may have potential for treating AD since the compounds are not only capable of alleviating cognitive deficits in animal models of cognitive impairment (see above) but they can also provide neuroprotection against amyloid toxicity (see (72) for a review). Evidence for such neuroprotective activity has been provided both by *in vitro* experiments in cultured cortical neurons (73) and by *in vivo* studies in rodents (74) (75). Recently, it was found that sigma-1 receptor agonists can powerfully suppress microglial activation (76). Such compounds may therefore attenuate the inflammatory component in neurodegenerative diseases.

More applications of sigma-1 receptor agonists, e.g. in the treatment of depression, anxiety, psychosis, substance abuse, stroke and neuropathic pain are discussed in several recent reviews (77) (78) (79) (80) (29) (81). Companies involved in the development of drugs for such indications include M's Science, AGY Therapeutics, Otsuka American Pharmaceutical, and Sanofi-Aventis (78)

MODULATION OF GLUTAMATE RELEASE BY SIGMA-1 AGONISTS

Besides the well-known deficits of acetylcholine, the neurotransmitter glutamate can be reduced in AD. Both neurotransmitters are supposed to play vital roles in memory (82). It is thus of interest that sigma ligands are capable of modulating glutamate release in various areas of the brain.

The neurosteroid PREGS (which is supposed to act as a sigma-1 receptor agonist) and the sigma-1 receptor agonist (+)-pentazocine, but not the (-)-enantiomers of PREGS and pentazocine, or the inactive steroid isopregnanolone enhance the spontaneous release of glutamate in cultured hippocampal neurons. The sigma receptor antagonists haloperidol and BD1063 and a membrane-permeable calcium chelator block this effect of PREGS. These results suggest that hippocampal glutamate release can be enhanced via activation of presynaptic sigma-1 receptors and an elevation of the levels of intracellular Ca^{2+} (83). Later studies by another research group confirmed that the spontaneous release of glutamate is enhanced by PREGS both in the hippocampus and in prelimbic cortex, but not in the striatum. The effect of PREGS in the prelimbic cortex appears to be mediated via alpha-1 adrenergic and sigma-1 receptors, whereas the effect in the hippocampus is dependent on sigma-1 receptors only. Intracellular calcium released from the endoplasmic reticulum plays a key role in the enhancement of glutamate release (84). DHEA-S, another neurosteroid with sigma-1 receptor agonist action, also enhances the spontaneous release of glutamate in prelimbic cortex and hippocampus. The effect of this compound in the prelimbic cortex appears to be mediated via dopamine D_1 and sigma-1 receptors, whereas that in the hippocampus occurs only via sigma-1 receptors (85).

Brain-derived neurotrophic factor (BDNF)-induced glutamate release in cultured cortical neurons is potentiated by antidepressants with sigma-1 receptor agonist activity such as fluvoxamine and imipramine, and this potentiation is blocked by the sigma-1 receptor antagonist BD1047. Not only pharmacological activation but also overexpression of the sigma-1 receptor enhances BDNF-enhanced glutamate release. The sigma-1 receptor appears to play an important role in BDNF signaling leading to the release of glutamate, and the enhancement of glutamate release seems to occur via the PLC-gamma/ IP_3 / Ca^{2+} pathway (86).

Thus, sigma ligands represent a strategy for modulating glutamatergic activity within the mammalian brain, and such modulation could be an additional mechanism underlying the anti-amnesic action of sigma-1 receptor agonists.

MODULATION OF THE NMDA RESPONSE BY SIGMA-1 AGONISTS

NMDA receptors mediate the induction of LTP and long-term depression in various brain areas (i.e. long-lasting improvements and impairments of synaptic transmission) (87) (88) (89) (90). Such forms of synaptic plasticity are considered as important cellular mechanisms underlying learning and memory (91) (92) (93).

Pharmacological inhibition of NMDA receptor function, by administration of NMDA antagonists either directly into the brain or by systemic administration of compounds which can cross the blood-brain barrier, results in impaired spatial learning and nonspatial passive avoidance learning in rodents (94) (95) (96).

(97). Knockout mice lacking the NMDA receptor 1 gene in CA1 pyramidal cells of the hippocampus exhibit impaired spatial learning but unimpaired nonspatial learning (98). Apparently, NMDA-dependent strengthening of CA1 synapses is essential for the acquisition and storage of spatial memory.

In many studies, sigma-1 receptor agonists were shown to modulate responses induced by NMDA receptor activation in various brain areas such as the hippocampus and prefrontal cortex. Some responses are potentiated and others inhibited by sigma-1 receptor agonists. Sigma-1 receptor antagonists when administered alone are without any effect, but these compounds block the agonist-induced modulation.

For example, the electrophysiological response of pyramidal neurons in the CA3 region of the rat dorsal hippocampus to NMDA (excitatory activation) is potentiated by sigma-1 receptor agonists such as (+)pentazocine, DTG, BD737, igmesine, L687,384, or DHEA and therapeutic drugs with significant sigma-1 receptor agonist affinity (the SSRI sertraline and the monoamine oxidase inhibitor clorgyline), whereas this potentiation is reversed by sigma-1 receptor antagonists such as haloperidol, BMY14802, NE-100, progesterone and testosterone (99) (100) (101) (102) (103) (104) (105). The potentiation persists for at least 60 minutes and can be sustained by prolonged microiontophoretic application of a sigma-1 receptor agonist, indicating that sigma-1 receptors do not rapidly desensitize (99).

Steroid hormones with antagonist action such as progesterone and testosterone produce a tonic dampening of the function of sigma-1 receptors and, consequently, of NMDA-mediated responses. Pregnancy reduces sigma-1 receptor function in the brain, since a tenfold higher dose of sigma-1 receptor agonists is required to potentiate the NMDA-response of pyramidal neurons in pregnant female rats than in non-pregnant control animals (106).

In an electrophysiological study in which animals were unilaterally lesioned by local injection of colchicine into the mossy fiber system (an afferent system to CA3 pyramidal neurons), the potentiating effect of (+)-pentazocine on the NMDA-response was found to persist on the lesioned side, but the potentiating effects of DTG and igmesine were abolished after lesioning (107). These data were interpreted as suggesting that the test drugs were acting on two different subtypes of sigma receptors, and that the receptors for DTG and igmesine are located on the mossy fiber terminals, in contrast to the receptors for (+)-pentazocine (107). In a later study, the effect of the sigma-2 subtype-selective ligand siramesine was tested on the neuronal response to NMDA in the CA3 region of the rat dorsal hippocampus. Siramesine was found to potentiate the NMDA response dose-dependently with a bell-shaped curve, but the effect of siramesine could - in contrast to the effect of sigma-1 receptor agonists - not be reversed by NE-100, haloperidol or progesterone (108). Thus, not only sigma-1 but also sigma-2 receptors appear to be involved in modulation of the NMDA response.

Bell-shaped dose-response curves are a common finding in studies regarding the effect of sigma-1 receptor agonists. At low doses the NMDA response is

potentiated but at higher dose the potentiation is reversed (99) (109) (110) (103). For example, the sigma-1 receptor agonist SR 31742A increases NMDA-induced inward currents of pyramidal cells in slices of rat medial prefrontal cortex at doses ranging from 10 to 100 nM (EC_{50} 23 nM), but at doses greater than 100 nM an inhibition is observed (111). The potentiation of NMDA-receptor mediated neurotransmission by SR 31742A may account for the antipsychotic and cognition-enhancing properties of the drug, whereas the inhibition of NMDA responses at higher drug concentrations may account for its neuroprotective effect (112).

Recently, a molecular mechanism has been proposed which may explain how sigma-1 receptor ligands increase the NMDA response. Calcium ions entering the cells through NMDA-receptor-related channels normally activate a potassium current via small-conductance calcium-activated K^+ channels (SK channels). This current shunts the NMDA receptor responses. Sigma-1 subtype-selective receptor agonists prevent SK channel opening, and consequently increase the NMDA receptor response (113).

MODULATION OF CALCIUM HOMEOSTASIS

The intracellular localization of sigma-1 receptors (mainly in endoplasmatic reticulum, but also in nuclear and plasma membranes and on mitochondria (114) (115) (116) (117) (118)) suggests that these binding sites could be involved in the regulation of calcium mobilization.

Indeed, sigma-1 receptor activation has been shown to affect calcium homeostasis. Sigma-1 receptor agonists increased contractility, beating rate and calcium influx in cultured cardiac myocytes from neonatal rats (119). Intracellular levels of inositol triphosphate in these cells were increased as well (120). In NG108 (neuroblastoma-glioma) cells, various sigma-1 receptor agonists enhanced the bradykinin-induced increases in cytosolic free calcium with bell-shaped dose-response curves whereas this effect could be blocked by a sigma-1 receptor antisense oligonucleotide, suggesting that sigma-1 receptor activation facilitates IP_3 -receptor-mediated Ca^{2+} signaling (121). In SH-SY5Y (neuroblastoma) cells, the sigma-1 receptor agonist (+)-pentazocine and various neurosteroids also potentiated the bradykinin-induced Ca^{2+} response, and this potentiation was blocked by the sigma receptor antagonists haloperidol and progesterone (122). By expression of either complete sigma-1 receptors or the N- or C-terminal segment of the sigma-1 receptor protein in MCF-7 breast cancer cells (which normally express few sigma-1 receptors), proof was obtained that sigma-1 receptor overexpression results in an enhancement of bradykinin-, vasopressin- or ATP-induced calcium release, and that the C-terminal segment of the sigma-1 receptor is involved in the interaction with the inositol triphosphate receptor-ankyrin-B 220 complex (123).

Experiments in adult guinea pig isolated brainstem preparations have indicated that sigma-1 receptor activation leads to activation of phospholipase C and the beta-1 and beta-2 isoforms of protein kinase C (124). In isolated rat hippocampal

neurons, receptor activation leads to a potentiation of NMDA-receptor-mediated increases of free intracellular calcium (125). However, in rat frontal cortical neurons, sigma receptor ligands were found to *reduce* the NMDA-induced Ca^{2+} influx. Sigma-1-subtype-selective compounds (igmesine, (+)-pentazocine) particularly affected the sustained phase of the Ca^{2+} response to NMDA, whereas non-subtype-selective compounds (DTG, haloperidol) reduced the initial and sustained phases to the same degree. The inhibition of the sustained phase was directly related to the affinity of the ligands to sigma-1 receptors. Thus, in frontal cortical neurons, sigma-1 receptors appear to facilitate the desensitization of the Ca^{2+} response to NMDA (126). Attenuation of NMDA-induced calcium responses by sigma ligands in frontal cortical neurons was also observed in a later study, and that study confirmed that sigma ligands shifted the NMDA response from a sustained to a biphasic or transient event (127).

In an interesting study on the sigma-1 receptor agonist igmesine, the effect of intracerebroventricularly administered modulators of calcium influx and mobilization was examined on the reduction of immobilization time caused by igmesine in the forced swimming test. Using chelators of extracellular and intracellular calcium, L- and N-type voltage-dependent calcium channel antagonists and agonists, evidence was obtained that the antidepressant effect of igmesine is dependent not only on rapid Ca^{2+} influx (like that of classical antidepressants), but also on intracellular Ca^{2+} mobilization (128).

Antagonists of voltage-dependent calcium channels such as nimodipine impair the cognitive performance of rodents in various learning tests. Such impairments could be attenuated by pre-administration of the sigma-1 receptor agonists PRE-084, and this attenuation could be completely prevented by co-administration of the sigma-1 receptor antagonist BMY-14802. Thus, calcium fluxes are implied in memory processes and an impairment of calcium influx through voltage-dependent calcium channels can, at least partially, be overcome by administration of a sigma-1 receptor agonist (129). Potentiation or attenuation of calcium signaling via sigma-1 receptors (both Ca^{2+} entry at the plasma membrane level via channels and Ca^{2+} mobilization from intracellular stores) may explain why selective sigma-1 receptor agonists can modulate a wide variety of neuronal responses, and be the key mechanism by which sigma-1 receptors affect learning and memory (130).

INVOLVEMENT OF SIGMA-1 RECEPTORS IN NEURONAL DIFFERENTIATION AND NEUROPLASTICITY

Sigma-1 receptors are expressed not only in neurons but also in astrocytes and oligodendrocytes within the brain (131)·(132). Overexpression of sigma-1 receptors potentiates nerve growth factor (NGF)-induced neurite outgrowth in PC-12 cells, and

this effect can be blocked by sigma-1 receptor antisense (133). Sigma-1 receptors are strongly upregulated in the corpus callosum of developing brains, particularly in the phase of active myelination (134). A high expression of these binding sites is observed in oligodendrocytes (135) and Schwann cells (136), suggesting involvement of the sigma-1 receptor in myelination. Knockdown of these receptors by siRNA results in complete inhibition of the differentiation and myelination of oligodendrocyte progenitor cells (137) and prevention of the formation of mature dendritic spines in hippocampal primary neurons (26). Eliprodil, a neuroprotective drug with a high affinity agonist action at sigma receptors, strongly promotes myelination in neuron-oligodendrocyte cocultures. These data suggest that upregulation of sigma-1 receptors is an important prerequisite for neuronal differentiation, and that sigma-1 receptor agonists like eliprodil may be of therapeutic interest in demyelinating diseases such as multiple sclerosis (138).

Overexpression of sigma-1 receptors promotes lipid reconstitution in the plasma membrane and potentiates raft-residing neurotrophic factors receptors and signal transduction (NGF, EGF, BDNF) (139)·(140)·(141)·(142). These neurotrophic factor signaling pathways may therefore be involved in the differentiation-promoting effects of sigma-1 receptors. When PC-12 cells are treated with NGF and verbenachalcone, a differentiation enhancer, the sigma-1 receptor belongs to the 10 (out of 10,000) genes showing the strongest upregulation (143). Since a very high expression of sigma-1 receptors has been noticed in the ventricular zone of young rat brains, where active proliferation and differentiation of cells occurs (144), sigma-1 receptors may not only play an important role in neuroplasticity but may also be involved in neurogenesis. An involvement of sigma-1 receptors in neurogenesis is suggested by the observation that continuous administration of the sigma-1 agonist SA4503 dose-dependently enhances the number of bromodeoxyuridine-positive cells in the subgranular zone of the adult rat hippocampus (by 48% at 3 mg/kg/d and by 94% at 10 mg/kg/d, respectively, after a treatment period of 3 days), indicating an increased cellular proliferation. Since SA4503 causes parallel increases of hippocampal 5-HT neurotransmission and cell proliferation, the neurotransmitter serotonin may play a central role in the proliferation process (145).

Not only sigma-1 receptor overexpression, but also drug-induced sigma-1 receptor activation results in potentiation of NGF-induced neurite outgrowth. Donepezil, a combined sigma-1 receptor ligand and AChE inhibitor (IC_{50} values 14.6 nM and 21.5 nM, respectively (146)), potentiates NGF-induced neurite outgrowth in PC12 cells, and this effect of donepezil can be blocked by the sigma-1 receptor antagonist NE-100 or the inositol 1,4,5-triphosphate (IP_3)-receptor antagonist xestospongine C (147), but is not affected by cholinergic antagonists (mecamylamine, scopolamine) or cholinomimetic drugs (nicotine, carbachol) (148). Physostigmine, an AChE inhibitor without sigma-1 receptor affinity, does not alter NGF-induced neurite outgrowth (149). The SSRI fluvoxamine (but not

the SSRIs sertraline or paroxetine) and the sigma-1 receptor agonists SA4503, PPBP and DHEA-sulfate likewise potentiate neurite outgrowth in PC12 cells in a concentration-dependent manner, and the effect of these drugs can also be blocked by NE-100 or xestospongin C (150). Since sertraline and fluvoxamine have similar affinities to sigma-1 receptors (69) but only fluvoxamine promotes outgrowth, these data may indicate that sertraline is a sigma-1 receptor antagonist and fluvoxamine a sigma-1 receptor agonist (150). Specific inhibitors of phospholipase C (PLC), phosphatidyl inositol 3-kinase (PI3K), p38 mitogen-activated protein kinase (p38MAPK), c-Jun terminal kinase (JNK), and the Ras/Raf/mitogen-activated protein kinase signaling pathways block the potentiation of NGF-induced neurite outgrowth as well (150). Apparently, both sigma-1 receptors and IP₃-receptors are involved in the potentiation of neurite outgrowth by the test drugs, besides the PLC, PI3K, p38MAPK, JNK and the Ras/Raf/MAPk signaling pathways.

2

CONCLUSION

Because of the neuromodulatory role of sigma-1 receptors, ligands for these binding sites can affect a large variety of cerebral processes. Modification of calcium transients (both by affecting calcium release from intracellular stores and influx of extracellular calcium) and modulation of potassium channel activity via direct protein-protein interaction appear to be key processes underlying the action of sigma-1 receptor ligands. Probably via these mechanisms, several neurotransmitter systems are modulated, particularly the cholinergic and glutamatergic (NMDA-receptor) pathways. The modulatory role of sigma-1 receptors explains why sigma-1 receptor ligands are usually devoid of an effect under control conditions but have striking effects when the normal homeostasis of the organism has been disturbed, e.g. by disease or by a pharmacological challenge. Data from preclinical studies in a large variety of animal models suggests that sigma-1 receptor agonists are promising compounds for the treatment of cognitive dysfunction.

REFERENCES

1. Aigner TG. Pharmacology of memory: cholinergic-glutamatergic interactions. *Curr Opin Neurobiol.* 1995;5(2):155-160.
2. Gallagher M, Colombo PJ. Ageing: the cholinergic hypothesis of cognitive decline. *Curr Opin Neurobiol.* 1995;5(2):161-168.
3. Bartus RT, Dean RL, III, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. *Science.* 1982;217(4558):408-414.
4. Coyle JT, Price DL, DeLong MR. Alzheimer's disease: a disorder of cortical cholinergic innervation. *Science.* 1983;219(4589):1184-1190.
5. Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. *Lancet.* 1976;2(8000):1403.
6. Patel S, Tariot PN. Pharmacologic models of Alzheimer's disease. *Psychiatr Clin North Am.* 1991;14(2):287-308.
7. Krall WJ, Sramek JJ, Cutler NR. Cholinesterase inhibitors: a therapeutic strategy for Alzheimer disease. *Ann Pharmacother.* 1999;33(4):441-450.
8. Hayashi T, Su T. The sigma receptor: evolution of the concept in neuropsychopharmacology. *Curr Neuropsychopharmacol.* 2005;3(4):267-280.
9. Hayashi T, Su TP. Sigma-1 receptors at galactosylceramide-enriched lipid microdomains regulate oligodendrocyte differentiation. *Proc Natl Acad Sci U S A.* 2004;101(41):14949-14954.
10. Maurice T. Neurosteroids and sigma1 receptors, biochemical and behavioral relevance. *Pharmacopsychiatry.* 2004;37 Suppl 3:S171-S182.
11. Maurice T, Phan VL, Urani A, Kamei H, Noda Y, Nabeshima T. Neuroactive neurosteroids as endogenous effectors for the sigma1 (sigma1) receptor: pharmacological evidence and therapeutic opportunities. *Jpn J Pharmacol.* 1999;81(2):125-155.
12. Maurice T, Urani A, Phan VL, Romieu P. The interaction between neuroactive steroids and the sigma1 receptor function: behavioral consequences and therapeutic opportunities. *Brain Res Brain Res Rev.* 2001;37(1-3):116-132.
13. Su TP, London ED, Jaffe JH. Steroid binding at sigma receptors suggests a link between endocrine, nervous, and immune systems [see comments]. *Science.* 1988;240(4849):219-221.
14. Ramachandran S, Chu UB, Mavlyutov TA, Pal A, Pyne S, Ruoho AE. The sigma1 receptor interacts with N-alkyl amines and endogenous sphingolipids. *Eur J Pharmacol.* 2009;609(1-3):19-26.
15. Maurice T, Su TP. The pharmacology of sigma-1 receptors. *Pharmacol Ther.* 2009.
16. Hayashi T, Su TP. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival. *Cell.* 2007;131(3):596-610.
17. Horan B, Gifford AN, Matsuno K, Mita S, Ashby CR. Effect of SA4503 on the electrically evoked release of 3H-acetylcholine from striatal and hippocampal rat brain slices. *Synapse.* 2002;46(1):1-3.
18. Junien JL, Roman FJ, Brunelle G, Pascaud X. JO1784, a novel sigma ligand, potentiates [3H]acetylcholine release from rat hippocampal slices. *Eur J Pharmacol.* 1991;200(2-3):343-345.
19. Kobayashi T, Matsuno K, Nakata K, Mita S. Enhancement of acetylcholine release by SA4503, a novel sigma 1 receptor agonist, in the rat brain. *J Pharmacol Exp Ther.* 1996;279(1):106-113.
20. Meyer DA, Carta M, Partridge LD, Covey DF, Valenzuela CF. Neurosteroids enhance spontaneous glutamate release in hippocampal neurons - Possible role of metabotropic sigma(1)-like receptors. *J Biol Chem.* 2002;277(32):28725-28732.
21. Hayashi T, Su TP. Intracellular dynamics of sigma(1) receptors (sigma(1) binding sites) in NG108-15 cells. *J Pharmacol Exp Ther.* 2003;306(2):726-733.
22. Hayashi T, Su TP. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival. *Cell.* 2007;131(3):596-610.

23. Hayashi T, Su TP. Sigma-1 receptors at galactosylceramide-enriched lipid microdomains regulate oligodendrocyte differentiation. *Proc Natl Acad Sci U S A*. 2004;101(41):14949-14954.
24. Hayashi T, Su TP. An update on the development of drugs for neuropsychiatric disorders: focusing on the sigma(1) receptor ligand. *Expert Opin Ther Targets*. 2008;12(1):45-58.
25. Takebayashi M, Hayashi T, Su TP. A perspective on the new mechanism of antidepressants: neuritogenesis through sigma-1 receptors. *Pharmacopsychiatry*. 2004;37 Suppl 3:S208-S213.
26. Tsai SY, Hayashi T, Su TP. Hippocampal dendritogenesis and associated anchoring of NMDA and AMPA receptors are controlled by sigma-1 receptors [abstract]. *Int J Neuropsychopharmacol*. 2006;9(Suppl 1):S213.
27. Marrazzo A, Caraci F, Salinaro ET, Su TP, Copani A, Ronsisvalle G. Neuroprotective effects of sigma-1 receptor agonists against beta-amyloid-induced toxicity. *Neuroreport*. 2005;16(11):1223-1226.
28. Maurice T, Lockhart BP. Neuroprotective and anti-amnesic potentials of sigma receptor ligands. *Prog Neuropsychopharmacol Biol Psychiatry*. 1997;21:69-102.
29. Maurice T. Cognitive effects of sigma-receptor ligands. In: Matsumoto RR, Bowen WD, Su TP, eds. *Sigma Receptors: Chemistry, Cell Biology and Clinical Implications*. New York: Springer; 2007:237-271.
30. Matsuno K, Matsunaga K, Mita S. Increase of extracellular acetylcholine level in rat frontal cortex induced by (+)N-allylnormetazocine as measured by brain microdialysis. *Brain Res*. 1992;575(2):315-319.
31. Matsuno K, Matsunaga K, Senda T, Mita S. Increase in extracellular acetylcholine level by sigma ligands in rat frontal cortex. *J Pharmacol Exp Ther*. 1993;265(2):851-859.
32. Matsuno K, Senda T, Kobayashi T, Mita S. Involvement of sigma 1 receptor in (+)N-allylnormetazocine-stimulated hippocampal cholinergic functions in rats. *Brain Res*. 1995;690(2):200-206.
33. Kobayashi T, Matsuno K, Mita S. Regional differences of the effect of sigma receptor ligands on the acetylcholine release in the rat brain. *J Neural Transm Gen Sect*. 1996;103(6):661-669.
34. Matsuno K, Senda T, Kobayashi T, Okamoto K, Nakata K, Mita S. SA4503, a novel cognitive enhancer, with sigma-1 receptor agonistic properties. *Behav Brain Res*. 1997;83:221-224.
35. Antonini V, Prezzavento O, Coradazzi M et al. Anti-amnesic properties of (+/-)-PPCC, a novel sigma receptor ligand, on cognitive dysfunction induced by selective cholinergic lesion in rats. *J Neurochem*. 2009;109(3):744-754.
36. Antonini V, Prezzavento O, Coradazzi M et al. Anti-amnesic properties of (+/-)-PPCC, a novel sigma receptor ligand, on cognitive dysfunction induced by selective cholinergic lesion in rats. *J Neurochem*. 2009;109(3):744-754.
37. Kawamura K, Kimura Y, Tsukada H et al. An increase of sigma receptors in the aged monkey brain. *Neurobiol Aging*. 2003;24(5):745-752.
38. Ishii K, Kimura Y, Kawamura K, Oda K, Sasaki T, Ishiwata K. Mapping of sigma1 receptors by 11C-SA4503-distribution and aging effect in normal human brain. [abstract]. *Neuroimage*. 2002;16(3):S31.
39. Jansen KL, Faull RL, Storey P, Leslie RA. Loss of sigma binding sites in the CA1 area of the anterior hippocampus in Alzheimer's disease correlates with CA1 pyramidal cell loss. *Brain Res*. 1993;623(2):299-302.
40. Mishina M, Ohyama M, Ishii K et al. Low density of sigma1 receptors in early Alzheimer's disease. *Ann Nucl Med*. 2008;22(3):151-156.
41. Mishina M, Ohyama M, Ishii K et al. Low density of sigma1 receptors in early Alzheimer's disease. *Ann Nucl Med*. 2008;22(3):151-156.
42. Uchida N, Ujike H, Tanaka Y et al. A variant of the sigma receptor type-1 gene is a protective factor for Alzheimer

- disease. *Am J Geriatr Psychiatry*. 2005;13(12):1062-1066.
43. Maruszak A, Safranow K, Gacia M et al. Sigma receptor type 1 gene variation in a group of polish patients with Alzheimer's disease and mild cognitive impairment. *Dement Geriatr Cogn Disord*. 2007;23(6):432-438.
 44. Mishina M, Ishiwata K, Ishii K et al. Function of sigma1 receptors in Parkinson's disease. *Acta Neurol Scand*. 2005;112(2):103-107.
 45. Phan VL, Miyamoto Y, Nabeshima T, Maurice T. Age-related expression of sigma1 receptors and antidepressant efficacy of a selective agonist in the senescence-accelerated (SAM) mouse. *J Neurosci Res*. 2005;79(4):561-572.
 46. Urani A, Romieu P, Roman FJ, Maurice T. Enhanced antidepressant effect of sigma(1) (sigma(1)) receptor agonists in beta(25-35)-amyloid peptide-treated mice. *Behav Brain Res*. 2002;134(1-2):239-247.
 47. Urani A, Romieu P, Roman FJ et al. Enhanced antidepressant efficacy of sigma1 receptor agonists in rats after chronic intracerebroventricular infusion of beta-amyloid-(1-40) protein. *Eur J Pharmacol*. 2004;486(2):151-161.
 48. Phan VL, Urani A, Sandillon F, Privat A, Maurice T. Preserved sigma1 (sigma1) receptor expression and behavioral efficacy in the aged C57BL/6 mouse. *Neurobiol Aging*. 2003;24(6):865-881.
 49. Ishiwata K, Kobayashi T, Kawamura K, Matsuno K. Age-related changes of the binding of [3h]SA4503 to sigma1 receptors in the rat brain. *Ann Nucl Med*. 2003;17(1):73-77.
 50. Majewska MD, Parameswaran S, Vu T, London ED. Divergent ontogeny of sigma and phencyclidine binding sites in the rat brain. *Brain Res Dev Brain Res*. 1989;47(1):13-18.
 51. Matsumoto RR, Bowen WD, Walker JM. Age-related differences in the sensitivity of rats to a selective sigma ligand. *Brain Res*. 1989;504:145-148.
 52. Paleos GA, Yang ZW, Byrd JC. Ontogeny of PCP and sigma receptors in rat brain. *Brain Res Dev Brain Res*. 1990;51(2):147-152.
 53. Matsuno K, Senda T, Matsunaga K, Mita S. Ameliorating effects of sigma receptor ligands on the impairment of passive avoidance tasks in mice: involvement in the central acetylcholinergic system. *Eur J Pharmacol*. 1994;261(1-2):43-51.
 54. Matsuno K, Senda T, Matsunaga K, Mita S, Kaneto H. Similar ameliorating effects of benzomorphan and 5-HT2 antagonists on drug-induced impairment of passive avoidance response in mice: comparison with acetylcholinesterase inhibitors. *Psychopharmacology Berl*. 1993;112(1):134-141.
 55. Maurice T, Phan VL, Privat A. The anti-amnesic effects of sigma1 (sigma1) receptor agonists confirmed by in vivo antisense strategy in the mouse. *Brain Res*. 2001;898(1):113-121.
 56. Senda T, Matsuno K, Kobayashi T, Mita S. Reduction of the scopolamine-induced impairment of passive- avoidance performance by sigma receptor agonist in mice. *Physiol Behav*. 1997;61(2):257-264.
 57. Nabeshima T, Katoh A, Ishimaru H et al. Carbon monoxide-induced delayed amnesia, delayed neuronal death and change in acetylcholine concentration in mice. *J Pharmacol Exp Ther*. 1991;256(1):378-384.
 58. Brown AW, Aldridge WN, Street BW, Verschoyle RD. The behavioral and neuropathologic sequelae of intoxication by trimethyltin compounds in the rat. *Am J Pathol*. 1979;97(1):59-82.
 59. Chang LW, Dyer RS. A time-course study of trimethyltin induced neuropathology in rats. *Neurobehav Toxicol Teratol*. 1983;5(4):443-459.
 60. Maurice T, Phan VL, Privat A. The anti-amnesic effects of sigma1 (sigma1) receptor agonists confirmed by in vivo antisense strategy in the mouse. *Brain Res*. 2001;898(1):113-121.
 61. Maurice T, Phan VL, Urani A, Guillemain I. Differential involvement of the sigma(1) (sigma(1)) receptor in the anti-amnesic effect of neuroactive

- steroids, as demonstrated using an in vivo antisense strategy in the mouse. *Br J Pharmacol.* 2001;134(8):1731-1741.
62. Reddy DS, Kulkarni SK. The effects of neurosteroids on acquisition and retention of a modified passive-avoidance learning task in mice. *Brain Res.* 1998;791(1-2):108-116.
 63. Chen L, Dai XN, Sokabe M. Chronic administration of dehydroepiandrosterone sulfate (DHEAS) primes for facilitated induction of long-term potentiation via sigma 1 (sigma1) receptor: optical imaging study in rat hippocampal slices. *Neuropharmacology.* 2006;50(3):380-392.
 64. Sabeti J, Nelson TE, Purdy RH, Gruol DL. Steroid pregnenolone sulfate enhances NMDA-receptor-independent long-term potentiation at hippocampal CA1 synapses: role for L-type calcium channels and sigma-receptors. *Hippocampus.* 2007;17(5):349-369.
 65. Chen L, Dai XN, Sokabe M. Chronic administration of dehydroepiandrosterone sulfate (DHEAS) primes for facilitated induction of long-term potentiation via sigma 1 (sigma1) receptor: optical imaging study in rat hippocampal slices. *Neuropharmacology.* 2006;50(3):380-392.
 66. Schiess AR, Partridge LD. Pregnenolone sulfate acts through a G-protein-coupled sigma1-like receptor to enhance short term facilitation in adult hippocampal neurons. *Eur J Pharmacol.* 2005;518(1):22-29.
 67. Hashimoto K, Fujita Y, Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine: role of sigma-1 receptors. *Neuropsychopharmacology.* 2007;32(3):514-521.
 68. Iyo M, Shirayama Y, Watanabe H et al. Fluvoxamine as a sigma-1 receptor agonist improved cognitive impairments in a patient with schizophrenia. *Prog Neuropsychopharmacol Biol Psychiatry.* 2008;32:1072-1073.
 69. Narita N, Hashimoto K, Tomitaka S, Minabe Y. Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain. *Eur J Pharmacol.* 1996;307:117-119.
 70. Ishikawa M, Ishiwata K, Ishii K et al. High Occupancy of Sigma-1 Receptors in the Human Brain after Single Oral Administration of Fluvoxamine: A Positron Emission Tomography Study Using [(11)C]SA4503. *Biol Psychiatry.* 2007;62(8):878-883.
 71. Ishikawa M, Sakata M, Ishii K et al. High occupancy of sigma1 receptors in the human brain after single oral administration of donepezil: a positron emission tomography study using [(11)C]SA4503. *Int J Neuropsychopharmacol.* 2009;12(8):1127-1131.
 72. Maurice T. Improving Alzheimer's Disease-Related Cognitive Deficits with sigma1 Receptor Agonists. *Drug News Perspect.* 2002;15(10):617-625.
 73. Marrazzo A, Caraci F, Salinaro ET, Su TP, Copani A, Ronsisvalle G. Neuroprotective effects of sigma-1 receptor agonists against beta-amyloid-induced toxicity. *Neuroreport.* 2005;16(11):1223-1226.
 74. Meunier J, Ieni J, Maurice T. The anti-amnesic and neuroprotective effects of donepezil against amyloid beta(25-35) peptide-induced toxicity in mice involve an interaction with the sigma(1) receptor. *Br J Pharmacol.* 2006;149(8):998-1012.
 75. Villard V, Espallergues J, Keller E et al. Antiamnesic and Neuroprotective Effects of the Aminotetrahydrofuran Derivative ANAVEX1-41 Against Amyloid beta(25-35)-Induced Toxicity in Mice. *Neuropsychopharmacology.* 2009;34(6):1552-1566.
 76. Hall AA, Herrera Y, Ajmo CT, Jr., Cuevas J, Pennypacker KR. Sigma receptors suppress multiple aspects of microglial activation. *Glia.* 2008;57(7):744-754.
 77. Cobos EJ, Entrena JM, Nieto FR, Cendan CM, Del Pozo E. Pharmacology and therapeutic potential of sigma(1) receptor ligands. *Curr Neuropharmacol.* 2008;6(4):344-366.
 78. Collier TL, Waterhouse RN, Kassiou M. Imaging sigma receptors: applications

- in drug development. *Curr Pharm Des.* 2007;13(1):51-72.
79. Hashimoto K, Ishiwata K. Sigma receptor ligands: possible application as therapeutic drugs and as radiopharmaceuticals. *Curr Pharm Des.* 2006;12(30):3857-3876.
 80. Hayashi T, Su TP. An update on the development of drugs for neuropsychiatric disorders: focusing on the sigma(1) receptor ligand. *Expert Opin Ther Targets.* 2008;12(1):45-58.
 81. Maurice T, Su TP. The pharmacology of sigma-1 receptors. *Pharmacol Ther.* 2009.
 82. Aigner TG. Pharmacology of memory: cholinergic-glutamatergic interactions. *Curr Opin Neurobiol.* 1995;5(2):155-160.
 83. Meyer DA, Carta M, Partridge LD, Covey DF, Valenzuela CF. Neurosteroids enhance spontaneous glutamate release in hippocampal neurons - Possible role of metabotropic sigma(1)-like receptors. *J Biol Chem.* 2002;277(32):28725-28732.
 84. Dong Y, Fu YM, Sun JL, Zhu YH, Sun FY, Zheng P. Neurosteroid enhances glutamate release in rat prelimbic cortex via activation of alpha1-adrenergic and sigma1 receptors. *Cell Mol Life Sci.* 2005;62(9):1003-1014.
 85. Dong LY, Cheng ZX, Fu YM et al. Neurosteroid dehydroepiandrosterone sulfate enhances spontaneous glutamate release in rat prelimbic cortex through activation of dopamine D1 and sigma-1 receptor. *Neuropharmacology.* 2007;52(3):966-974.
 86. Yagasaki Y, Numakawa T, Kumamaru E, Hayashi T, Su TP, Kunugi H. Chronic antidepressants potentiate via sigma-1 receptors the brain-derived neurotrophic factor-induced signaling for glutamate release. *J Biol Chem.* 2006;281(18):12941-12949.
 87. Artola A, Singer W. Long-term potentiation and NMDA receptors in rat visual cortex. *Nature.* 1987;330(6149):649-652.
 88. Collingridge G. Synaptic plasticity. The role of NMDA receptors in learning and memory. *Nature.* 1987;330(6149):604-605.
 89. Harris EW, Ganong AH, Cotman CW. Long-term potentiation in the hippocampus involves activation of N-methyl-D-aspartate receptors. *Brain Res.* 1984;323(1):132-137.
 90. Izquierdo I. Role of NMDA receptors in memory. *Trends Pharmacol Sci.* 1991;12(4):128-129.
 91. Bliss TV, Collingridge GL. A synaptic model of memory: long-term potentiation in the hippocampus. *Nature.* 1993;361(6407):31-39.
 92. Lynch MA. Long-term potentiation and memory. *Physiol Rev.* 2004;84(1):87-136.
 93. Teyler TJ. Long-term potentiation and memory. *Int J Neurol.* 1987;21-22:163-171.
 94. Cory-Slechta DA. The impact of NMDA receptor antagonists on learning and memory functions. *Psychopharmacol Bull.* 1994;30(4):601-612.
 95. Morris RG, Anderson E, Lynch GS, Baudry M. Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5. *Nature.* 1986;319(6056):774-776.
 96. Parada-Turska J, Turski WA. Excitatory amino acid antagonists and memory: effect of drugs acting at N-methyl-D-aspartate receptors in learning and memory tasks. *Neuropharmacology.* 1990;29(12):1111-1116.
 97. Venable N, Kelly PH. Effects of NMDA receptor antagonists on passive avoidance learning and retrieval in rats and mice. *Psychopharmacology (Berl).* 1990;100(2):215-221.
 98. Tsien JZ, Huerta PT, Tonegawa S. The essential role of hippocampal CA1 NMDA receptor-dependent synaptic plasticity in spatial memory. *Cell.* 1996;87(7):1327-1338.
 99. Bergeron R, de Montigny C, Debonnel G. Biphasic effects of sigma ligands on the neuronal response to N-methyl-D-aspartate. *Naunyn Schmiedeberg's Arch Pharmacol.* 1995;351(3):252-260.
 100. Bergeron R, de Montigny C, Debonnel G. Potentiation of neuronal NMDA response induced by dehydroepiandrosterone

- and its suppression by progesterone: effects mediated via sigma receptors. *J Neurosci.* 1996;16:1193-1202.
101. Bergeron R, Debonnel G, de Montigny C. Modification of the N-methyl-D-aspartate response by antidepressant sigma receptor ligands. *Eur J Pharmacol.* 1993;240(2-3):319-323.
 102. Debonnel G, Bergeron R, de Montigny C. Potentiation by dehydroepiandrosterone of the neuronal response to N-methyl-D-aspartate in the CA3 region of the rat dorsal hippocampus: an effect mediated via sigma receptors. *J Endocrinol.* 1996;150 Suppl:S33-42.
 103. Monnet FP, Debonnel G, de Montigny C. In vivo electrophysiological evidence for a selective modulation of N-methyl-D-aspartate-induced neuronal activation in rat CA3 dorsal hippocampus by sigma ligands. *J Pharmacol Exp Ther.* 1992;261(1):123-130.
 104. Monnet FP, Debonnel G, Fournier A, de Montigny C. Neuropeptide Y potentiates the N-methyl-D-aspartate response in the CA3 dorsal hippocampus. II. Involvement of a subtype of sigma receptor. *J Pharmacol Exp Ther.* 1992;263(3):1219-1225.
 105. Monnet FP, Debonnel G, Junien JL, de Montigny C. N-methyl-D-aspartate-induced neuronal activation is selectively modulated by sigma receptors. *Eur J Pharmacol.* 1990;179(3):441-445.
 106. Bergeron R, de Montigny C, Debonnel G. Pregnancy reduces brain sigma receptor function. *Br J Pharmacol.* 1999;127(8):1769-1776.
 107. Debonnel G, Bergeron R, Monnet FP, de Montigny C. Differential effects of sigma ligands on the N-methyl-D-aspartate response in the CA1 and CA3 regions of the dorsal hippocampus: effect of mossy fiber lesioning. *Neuroscience.* 1996;71(4):977-987.
 108. Couture S, Debonnel G. Modulation of the neuronal response to N-methyl-D-aspartate by selective sigma2 ligands. *Synapse.* 1998;29(1):62-71.
 109. Bergeron R, Debonnel G, de Montigny C. Modification of the N-methyl-D-aspartate response by antidepressant sigma receptor ligands. *Eur J Pharmacol.* 1993;240(2-3):319-323.
 110. Monnet FP, de Costa BR, Bowen WD. Differentiation of sigma ligand-activated receptor subtypes that modulate NMDA-evoked [3H]-noradrenaline release in rat hippocampal slices. *Br J Pharmacol.* 1996;119(1):65-72.
 111. Liang X, Wang RY. Biphasic modulatory action of the selective sigma receptor ligand SR 31742A on N-methyl-D-aspartate-induced neuronal responses in the frontal cortex. *Brain Res.* 1998;807(1-2):208-213.
 112. Liang X, Wang RY. Biphasic modulatory action of the selective sigma receptor ligand SR 31742A on N-methyl-D-aspartate-induced neuronal responses in the frontal cortex. *Brain Res.* 1998;807(1-2):208-213.
 113. Martina M, Turcotte ME, Halman S, Bergeron R. The sigma-1 receptor modulates NMDA receptor synaptic transmission and plasticity via SK channels in rat hippocampus. *J Physiol.* 2007;578(Pt 1):143-157.
 114. Itzhak Y, Stein I, Zhang SH, Kassim CO, Cristante D. Binding of sigma-ligands to C57BL/6 mouse brain membranes: effects of monoamine oxidase inhibitors and subcellular distribution studies suggest the existence of sigma-receptor subtypes. *J Pharmacol Exp Ther.* 1991;257(1):141-148.
 115. Jiang G, Mysona B, Dun Y et al. Expression, subcellular localization, and regulation of sigma receptor in retinal muller cells. *Invest Ophthalmol Vis Sci.* 2006;47(12):5576-5582.
 116. McCann DJ, Su TP. Haloperidol-sensitive (+)[3H]SKF-10,047 binding sites (sigma sites) exhibit a unique distribution in rat brain subcellular fractions. *Eur J Pharmacol.* 1990;188(4-5):211-218.
 117. Phan VL, Urani A, Sandillon F, Privat A, Maurice T. Preserved sigma1 (sigma1) receptor expression and behavioral efficacy in the aged C57BL/6 mouse. *Neurobiol Aging.* 2003;24(6):865-881.
 118. Samovilova NN, Vinogradov VA. Subcellular distribution of (+)-[3H]SKF

- 10,047 binding sites in rat liver. *Eur J Pharmacol.* 1992;225(1):69-74.
119. Ela C, Barg J, Vogel Z, Hasin Y, Eilam Y. Sigma receptor ligands modulate contractility, Ca⁺⁺ influx and beating rate in cultured cardiac myocytes. *J Pharmacol Exp Ther.* 1994;269(3):1300-1309.
 120. Novakova M, Ela C, Bowen WD, Hasin Y, Eilam Y. Highly selective sigma receptor ligands elevate inositol 1,4,5- trisphosphate production in rat cardiac myocytes. *Eur J Pharmacol.* 1998;353(2-3):315-327.
 121. Hayashi T, Maurice T, Su TP. Ca(2+) signaling via sigma(1)-receptors: novel regulatory mechanism affecting intracellular Ca(2+) concentration. *J Pharmacol Exp Ther.* 2000;293(3):788-798.
 122. Hong W, Nuwayhid SJ, Werling LL. Modulation of bradykinin-induced calcium changes in SH-SY5Y cells by neurosteroids and sigma receptor ligands via a shared mechanism. *Synapse.* 2004;54(2):102-110.
 123. Wu Z, Bowen WD. Role of sigma-1 receptor C-terminal segment in IP3 receptor activation: Constitutive enhancement of calcium signaling in MCF-7 tumor cells. *J Biol Chem.* 2008;283:28198-28215.
 124. Morin-Surun MP, Collin T, Denavit-Saubie M, Baulieu EE, Monnet FP. Intracellular sigma(1) receptor modulates phospholipase C and protein kinase C activities in the brainstem. *Proceedings of the National Academy of Sciences of the United States of America.* 1999;96(14):8196-8199.
 125. Monnet FP, Morin-Surun MP, Leger J, Combettes L. Protein kinase C-dependent potentiation of intracellular calcium influx by sigma1 receptor agonists in rat hippocampal neurons. *J Pharmacol Exp Ther.* 2003;307(2):705-712.
 126. Hayashi T, Kagaya A, Takebayashi M et al. Modulation by sigma ligands of intracellular free Ca⁺⁺ mobilization by N-methyl-D-aspartate in primary culture of rat frontal cortical neurons. *J Pharmacol Exp Ther.* 1995;275(1):207-214.
 127. Klette KL, Lin Y, Clapp LE, DeCoster MA, Moreton JE, Tortella FC. Neuroprotective sigma ligands attenuate NMDA and trans-ACPD- induced calcium signaling in rat primary neurons. *Brain Res.* 1997;756(1-2):231-240.
 128. Urani A, Romieu P, Portales-Casamar E, Roman FJ, Maurice T. The antidepressant-like effect induced by the sigma(1) (sigma(1)) receptor agonist igmesine involves modulation of intracellular calcium mobilization. *Psychopharmacology (Berl).* 2002;163(1):26-35.
 129. Maurice T, Su TP, Parish DW, Privat A. Prevention of nimodipine-induced impairment of learning by the selective sigma ligand PRE-084. *J Neural Transm Gen Sect.* 1995;102:1-18.
 130. Monnet FP. Sigma-1 receptor as regulator of neuronal intracellular Ca²⁺: clinical and therapeutic relevance. *Biol Cell.* 2005;97(12):873-883.
 131. Hayashi T, Su T. The sigma receptor: evolution of the concept in neuropsychopharmacology. *Curr Neuropharmacol.* 2005;3(4):267-280.
 132. Hayashi T, Su TP. Sigma-1 receptors at galactosylceramide-enriched lipid microdomains regulate oligodendrocyte differentiation. *Proc Natl Acad Sci U S A.* 2004;101(41):14949-14954.
 133. Takebayashi M, Hayashi T, Su TP. Nerve growth factor-induced neurite sprouting in PC12 cells involves sigma-1 receptors: implications for antidepressants. *J Pharmacol Exp Ther.* 2002;303(3):1227-1237.
 134. Hayashi T, Su TP. Sigma-1 receptors at galactosylceramide-enriched lipid microdomains regulate oligodendrocyte differentiation. *Proc Natl Acad Sci U S A.* 2004;101(41):14949-14954.
 135. Palacios G, Muro A, Vela JM et al. Immunohistochemical localization of the sigma1-receptor in oligodendrocytes in the rat central nervous system. *Brain Res.* 2003;961(1):92-99.
 136. Palacios G, Muro A, Verdu E, Pumarola M, Vela JM. Immunohistochemical localization of the sigma1 receptor in

- Schwann cells of rat sciatic nerve. *Brain Res.* 2004;1007(1-2):65-70.
137. Hayashi T, Su TP. Sigma-1 receptors at galactosylceramide-enriched lipid microdomains regulate oligodendrocyte differentiation. *Proc Natl Acad Sci U S A.* 2004;101(41):14949-14954.
 138. Demerens C, Stankoff B, Zalc B, Lubetzki C. Eliprodil stimulates CNS myelination: new prospects for multiple sclerosis? *Neurology.* 1999;52(2):346-350.
 139. Hayashi T, Su TP. The potential role of sigma-1 receptors in lipid transport and lipid raft reconstitution in the brain: implication for drug abuse. *Life Sci.* 2005;77(14):1612-1624.
 140. Takebayashi M, Hayashi T, Su TP. A perspective on the new mechanism of antidepressants: neuritogenesis through sigma-1 receptors. *Pharmacopsychiatry.* 2004;37 Suppl 3:S208-S213.
 141. Takebayashi M, Hayashi T, Su TP. sigma-1 receptors potentiate epidermal growth factor signaling towards neuritogenesis in PC12 cells: Potential relation to lipid raft reconstitution. *Synapse.* 2004;53(2):90-103.
 142. Yagasaki Y, Numakawa T, Kumamaru E, Hayashi T, Su TP, Kunugi H. Chronic antidepressants potentiate via sigma-1 receptors the brain-derived neurotrophic factor-induced signaling for glutamate release. *J Biol Chem.* 2006;281(18):12941-12949.
 143. Yeh LA, Padmanaban D, Ho P et al. Effects of a verbenachalcone derivative on neurite outgrowth, inhibition of caspase induction and gene expression. *Bioorg Med Chem Lett.* 2005;15(4):1193-1196.
 144. Hayashi T, Su TP. Sigma-1 receptors at galactosylceramide-enriched lipid microdomains regulate oligodendrocyte differentiation. *Proc Natl Acad Sci U S A.* 2004;101(41):14949-14954.
 145. Lucas G, Rymar VV, Sadikot AF, Debonnel G. Further evidence for an antidepressant potential of the selective sigma1 agonist SA 4503: electrophysiological, morphological and behavioural studies. *Int J Neuropsychopharmacol.* 2008;11(4):485-495.
 146. Kato K, Hayako H, Ishihara Y, Marui S, Iwane M, Miyamoto M. TAK-147, an acetylcholinesterase inhibitor, increases choline acetyltransferase activity in cultured rat septal cholinergic neurons. *Neurosci Lett.* 1999;260(1):5-8.
 147. Ishima T, Nishimura T, Iyo M, Hashimoto K. Potentiation of nerve growth factor-induced neurite outgrowth in PC12 cells by donepezil: Role of sigma-1 receptors and IP(3) receptors. *Prog Neuropsychopharmacol Biol Psychiatry.* 2008;32:1656-1659.
 148. Oda T, Kume T, Katsuki H, Niidome T, Sugimoto H, Akaike A. Donepezil potentiates nerve growth factor-induced neurite outgrowth in PC12 cells. *J Pharmacol Sci.* 2007;104(4):349-354.
 149. Ishima T, Nishimura T, Iyo M, Hashimoto K. Potentiation of nerve growth factor-induced neurite outgrowth in PC12 cells by donepezil: Role of sigma-1 receptors and IP(3) receptors. *Prog Neuropsychopharmacol Biol Psychiatry.* 2008;32:1656-1659.
 150. Nishimura T, Ishima T, Iyo M, Hashimoto K. Potentiation of nerve growth factor-induced neurite outgrowth by fluvoxamine: role of sigma-1 receptors, IP3 receptors and cellular signaling pathways. *PLoS ONE.* 2008;3(7):e2558.
 151. Earley B, Burke M, Leonard BE, Gouret CJ, Junien JL. Evidence for an anti-amnesic effect of JO 1784 in the rat: a potent and selective ligand for the sigma receptor. *Brain Res.* 1991;546(2):282-286.
 152. Senda T, Matsuno K, Okamoto K, Kobayashi T, Nakata K, Mita S. Ameliorating effect of SA4503, a novel sigma 1 receptor agonist, on memory impairments induced by cholinergic dysfunction in rats. *Eur J Pharmacol.* 1996;315(1):1-10.
 153. Senda T, Matsuno K, Kobayashi T, Nakazawa M, Nakata K, Mita S. Ameliorative effect of SA4503, a novel cognitive enhancer, on the basal forebrain lesion-induced impairment of the spatial learning performance in rats. *Pharmacol Biochem Behav.* 1998;59(1):129-134.
 154. Urani A, Privat A, Maurice T. The modulation by neurosteroids of the scopolamine-induced learning

- impairment in mice involves an interaction with sigma1 (sigma1) receptors. *Brain Res.* 1998;799(1):64-77.
155. Maurice T, Phan VL, Privat A. The anti-amnesic effects of sigma1 (sigma1) receptor agonists confirmed by in vivo antisense strategy in the mouse. *Brain Res.* 2001;898(1):113-121.
 156. Tottori K, Nakai M, Uwahodo Y et al. Attenuation of scopolamine-induced and age-associated memory impairments by the sigma and 5-hydroxytryptamine (1A) receptor agonist OPC-14523 (1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-methoxy-3,4-dihydro-2[1H]-quinolinone monomethanesulfonate). *J Pharmacol Exp Ther.* 2002;301(1):249-257.
 157. Ivkovic M, Damjanovic A, Jasovic-Gasic M, Paunovic VR. The effects of fluoxetine on cognitive functions in animal model of Alzheimer's disease. *Psychiatr Danub.* 2004;16(1-2):15-20.
 158. Hiramatsu M, Hoshino T, Kameyama T, Nabeshima T. Involvement of kappa-opioid and sigma receptors in short-term memory in mice. *Eur J Pharmacol.* 2002;453(1):91-98.
 159. Hiramatsu M, Hoshino T. Involvement of kappa-opioid receptors and sigma receptors in memory function demonstrated using an antisense strategy. *Brain Res.* 2004;1030(2):247-255.
 160. Hiramatsu M, Hoshino T. Improvement of memory impairment by (+)- and (-)-pentazocine via sigma, but not kappa opioid receptors. *Brain Res.* 2005;1057(1-2):72-80.
 161. Espallergues J, Lapalud P, Christopoulos A et al. Involvement of the sigma1 (sigma1) receptor in the anti-amnesic, but not antidepressant-like, effects of the aminotetrahydrofuran derivative ANAVEX1-41. *Br J Pharmacol.* 2007;152(2):267-279.
 162. Wang HH, Chien JW, Chou YC, Liao JF, Chen CF. Anti-amnesic effect of dimemorfan in mice. *Br J Pharmacol.* 2003;138(5):941-949.
 163. Antonini V, Prezzavento O, Coradazzi M et al. Anti-amnesic properties of (+/-)-PPCC, a novel sigma receptor ligand, on cognitive dysfunction induced by selective cholinergic lesion in rats. *J Neurochem.* 2009;109(3):744-754.
 164. Mamiya T, Noda Y, Noda A et al. Effects of sigma receptor agonists on the impairment of spontaneous alternation behavior and decrease of cyclic GMP level induced by nitric oxide synthase inhibitors in mice [In Process Citation]. *Neuropharmacology.* 2000;39(12):2391-2398.
 165. Maurice T, Su TP, Privat A. Sigma1 (sigma 1) receptor agonists and neurosteroids attenuate B25-35-amyloid peptide-induced amnesia in mice through a common mechanism. *Neuroscience.* 1998;83(2):413-428.
 166. Meunier J, Ieni J, Maurice T. The anti-amnesic and neuroprotective effects of donepezil against amyloid beta(25-35) peptide-induced toxicity in mice involve an interaction with the sigma(1) receptor. *Br J Pharmacol.* 2006;149(8):998-1012.
 167. Wang HH, Chien JW, Chou YC, Liao JF, Chen CF. Anti-amnesic effect of dimemorfan in mice. *Br J Pharmacol.* 2003;138(5):941-949.
 168. Maurice T, Roman FJ, Su TP, Privat A. Beneficial effects of sigma agonists on the age-related learning impairment in the senescence-accelerated mouse (SAM). *Brain Res.* 1996;733(2):219-230.
 169. Maurice T. Beneficial effect of the sigma(1) receptor agonist PRE-084 against the spatial learning deficits in aged rats. *Eur J Pharmacol.* 2001;431(2):223-227.
 170. Tottori K, Nakai M, Uwahodo Y et al. Attenuation of scopolamine-induced and age-associated memory impairments by the sigma and 5-hydroxytryptamine (1A) receptor agonist OPC-14523 (1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-methoxy-3,4-dihydro-2[1H]-quinolinone monomethanesulfonate). *J Pharmacol Exp Ther.* 2002;301(1):249-257.
 171. Phan VL, Urani A, Sandillon F, Privat A, Maurice T. Preserved sigma1 (sigma1) receptor expression and behavioral

- efficacy in the aged C57BL/6 mouse. *Neurobiol Aging*. 2003;24(6):865-881.
172. Maurice T, Hiramatsu M, Kameyama T, Hasegawa T, Nabeshima T. Behavioral evidence for a modulating role of sigma ligands in memory processes. II. Reversion of carbon monoxide-induced amnesia. *Brain Res*. 1994;647(1):57-64.
 173. Maurice T, Phan VL, Noda Y, Yamada K, Privat A, Nabeshima T. The attenuation of learning impairments induced after exposure to CO or trimethyltin in mice by sigma (sigma) receptor ligands involves both sigma1 and sigma2 sites. *Br J Pharmacol*. 1999;127(2):335-342.
 174. Maurice T, Phan V, Sandillon F, Urani A. Differential effect of dehydroepiandrosterone and its steroid precursor pregnenolone against the behavioural deficits in CO-exposed mice. *Eur J Pharmacol*. 2000;390(1-2):145-155.
 175. Meunier J, Ieni J, Maurice T. Antiamnesic and neuroprotective effects of donepezil against learning impairments induced in mice by exposure to carbon monoxide gas. *J Pharmacol Exp Ther*. 2006;317(3):1307-1319.
 176. O'Connell AW, Earley B, Leonard BE. The sigma ligand JO 1784 prevents trimethyltin-induced behavioural and sigma-receptor dysfunction in the rat. *Pharmacol Toxicol*. 1996;78(5):296-302.
 177. Maurice T, Phan VL, Noda Y, Yamada K, Privat A, Nabeshima T. The attenuation of learning impairments induced after exposure to CO or trimethyltin in mice by sigma (sigma) receptor ligands involves both sigma1 and sigma2 sites. *Br J Pharmacol*. 1999;127(2):335-342.
 178. Meunier J, Gue M, Recasens M, Maurice T. Attenuation by a sigma1 (sigma1) receptor agonist of the learning and memory deficits induced by a prenatal restraint stress in juvenile rats. *Br J Pharmacol*. 2004;142(4):689-700.
 179. Meunier J, Maurice T. Beneficial effects of the sigma1 receptor agonists igmesine and dehydroepiandrosterone against learning impairments in rats prenatally exposed to cocaine. *Neurotoxicol Teratol*. 2004;26(6):783-797.
 180. Maurice T, Hiramatsu M, Itoh J, Kameyama T, Hasegawa T, Nabeshima T. Behavioral evidence for a modulating role of sigma ligands in memory processes. I. Attenuation of dizocilpine (MK-801)-induced amnesia. *Brain Res*. 1994;647(1):44-56.
 181. Ohno M, Watanabe S. Intrahippocampal administration of (+)-SKF 10,047, a sigma ligand, reverses MK-801-induced impairment of working memory in rats. *Brain Res*. 1995;684:237-242.
 182. Maurice T, Junien JL, Privat A. Dehydroepiandrosterone sulfate attenuates dizocilpine-induced learning impairment in mice via sigma-1 receptors. *Behav Brain Res*. 1997;83:159-164.
 183. Maurice T, Privat A. SA4503, a novel cognitive enhancer with sigma1 receptor agonist properties, facilitates NMDA-receptor-dependent learning in mice. *Eur J Pharmacol*. 1997;328:9-18.
 184. Zou LB, Yamada K, Nabeshima T. Sigma receptor ligands (+)-SKF10,047 and SA4503 improve dizocilpine-induced spatial memory deficits in rats. *Eur J Pharmacol*. 1998;355(1):1-10.
 185. Zou L, Yamada K, Sasa M, Nakata Y, Nabeshima T. Effects of sigma(1) receptor agonist SA4503 and neuroactive steroids on performance in a radial arm maze task in rats [In Process Citation]. *Neuropharmacology*. 2000;39(9):1617-1627.
 186. Maurice T, Phan VL, Privat A. The anti-amnesic effects of sigma1 (sigma1) receptor agonists confirmed by in vivo antisense strategy in the mouse. *Brain Res*. 2001;898(1):113-121.
 187. Maurice T, Phan VL, Urani A, Guillemain I. Differential involvement of the sigma(1) (sigma(1)) receptor in the anti-amnesic effect of neuroactive steroids, as demonstrated using an in vivo antisense strategy in the mouse. *Br J Pharmacol*. 2001;134(8):1731-1741.
 188. Noda A, Noda Y, Kamei H et al. Phencyclidine impairs latent learning in mice: interaction between glutamatergic systems and sigma(1) receptors. *Neuropsychopharmacology*. 2001;24(4):451-460.

189. Maurice T, Meunier J, Feng B, Ieni J, Monaghan DT. Interaction with sigma(1) protein, but not N-methyl-D-aspartate receptor, is involved in the pharmacological activity of donepezil. *J Pharmacol Exp Ther*. 2006;317(2):606-614.
190. Hashimoto K, Fujita Y, Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine: role of sigma-1 receptors. *Neuropsychopharmacology*. 2007;32(3):514-521.
191. Kunitachi S, Fujita Y, Ishima T et al. Phencyclidine-induced cognitive deficits in mice are ameliorated by subsequent subchronic administration of donepezil: Role of sigma-1 receptors. *Brain Res*. 2009.
192. Matsuno K, Senda T, Kobayashi T, Murai M, Mita S. Reduction of 4-cyclohexyl-1-[(1R)-1,2-diphenylethyl]-piperazine-induced memory impairment of passive avoidance performance by sigma 1 receptor agonists in mice. *Methods Find Exp Clin Pharmacol*. 1998;20(7):575-580.
193. Cobos EJ, Entrena JM, Nieto FR, Cendan CM, Del Pozo E. Pharmacology and therapeutic potential of sigma(1) receptor ligands. *Curr Neuropharmacol*. 2008;6(4):344-366.
194. Hayashi T, Su TP. An update on the development of drugs for neuropsychiatric disorders: focusing on the sigma(1) receptor ligand. *Expert Opin Ther Targets*. 2008;12(1):45-58.
195. Kawamura K, Kimura Y, Tsukada H et al. An increase of sigma receptors in the aged monkey brain. *Neurobiol Aging*. 2003;24(5):745-752.
196. Norbury R, Travis MJ, Erlandsson K et al. In vivo imaging of muscarinic receptors in the aging female brain with (R,R)[123I]-I-QNB and single photon emission tomography. *Exp Gerontol*. 2005;40(3):137-145.
197. Sheline YI, Mintun MA, Moerlein SM, Snyder AZ. Greater loss of 5-HT(2A) receptors in midlife than in late life. *Am J Psychiatry*. 2002;159(3):430-435.
198. Inoue M, Suhara T, Sudo Y et al. Age-related reduction of extrastriatal dopamine D2 receptor measured by PET. *Life Sci*. 2001;69(9):1079-1084.

